Market Newsdesk

January 5, 2021 8:19 am

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $100M.

The PRV was granted to Rhythm by the U.S. Food and Drug Administration (FDA) with the approval of IMCIVREE™ (setmelanotide) for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing.

“Rhythm is focused on transforming the care of people living with rare genetic diseases of obesity,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. “The non-dilutive capital from the sale of our PRV provides an important source of additional funding to advance the continued development of setmelanotide as a precision medicine for people whose severe obesity and insatiable hunger may be caused by genetic variants associated with the melanocortin-4 (MC4R) receptor pathway.”

According to the agreement, Rhythm will receive an upfront payment of $100M upon the closing of the transaction, which is subject to customary closing conditions and is expected to occur following expiration of the applicable U.S. antitrust clearance requirements. Jefferies LLC acted as exclusive financial advisor to Rhythm on this transaction. Latham & Watkins LLP acted as legal advisor to Rhythm.

The non-dilutive funds expected from this transaction are in addition to the $201.8 million in cash, cash equivalents and short-term investments Rhythm reported as of September 30, 2020.

About the Rare Pediatric Disease Priority Review Voucher Program

The program is intended to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. A PRV may be issued to the sponsor of a rare pediatric disease product application and would entitle the holder to priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and could lead to an expedited approval. The sponsor receives the PRV upon approval of the rare pediatric disease product application and it can be sold without limitation, subject to applicable FDA requirements for filing and use.

About Rhythm Pharmaceuticals

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity. The company’s precision medicine, IMCIVREE™ (setmelanotide), has been approved by the FDA for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing. IMCIVREE is the first-ever FDA approved therapy for these rare genetic diseases of obesity. Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity. The Company is leveraging the Rhythm Engine and the largest known obesity DNA database – now with more than 30,000 sequencing samples – to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. For healthcare professionals, visit www.UNcommonObesity.com for more information. For patients and caregivers, visit www.LEADforRareObesity.com for more information. The company is based in Boston, MA.

IMCIVREE™ (setmelanotide) Indication

IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The condition must be confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

Limitations of Use

IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:

Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign;
Other types of obesity not related to POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.

Important Safety Information

WARNINGS AND PRECAUTIONS

Disturbance in Sexual Arousal: Sexual adverse reactions may occur in patients treated with IMCIVREE. Spontaneous penile erections in males and sexual adverse reactions in females occurred in clinical studies with IMCIVREE. Instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

Depression and Suicidal Ideation: Some drugs that target the central nervous system, such as IMCIVREE, may cause depression or suicidal ideation. Monitor patients for new onset or worsening of depression. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors.

Skin Pigmentation and Darkening of Pre-Existing Nevi: IMCIVREE may cause generalized increased skin pigmentation and darkening of pre-existing nevi due to its pharmacologic effect. This effect is reversible upon discontinuation of the drug. Perform a full body skin examination prior to initiation and periodically during treatment with IMCIVREE to monitor pre-existing and new skin pigmentary lesions.

Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥23%) were injection site reactions, skin hyperpigmentation, nausea, headache, diarrhea, abdominal pain, back pain, fatigue, vomiting, depression, upper respiratory tract infection, and spontaneous penile erection.

USE IN SPECIFIC POPULATIONS

Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.
Treatment with IMCIVREE is not recommended for use while breastfeeding.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See Full Prescribing Information for IMCIVREE.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the completion of the contemplated sale of the PRV (including the satisfaction of the conditions thereto), the potential, safety, efficacy, and regulatory and clinical progress of setmelanotide, and our business strategy and plans. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, the impact of our management transition, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our liquidity and expenses, the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies, clinical trials and commercialization prospects, and general economic conditions, and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Corporate Contact:

David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
[email protected]

Investor Contact:

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Contact:

Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]

January 5, 2021 8:19 am

CryptoStar Corp. Announces Closing of Non-Brokered Private Placement of Units

Canada NewsWire

TSXV: CSTR

TORONTO, Jan. 5, 2021 /CNW/ – CryptoStar Corp. (TSXV: CSTR) (“CryptoStar” or the “Company“), a cryptocurrency mining and data centre operator, today announced that it has closed the private placement announced on November 30, 2020, consisting of the issuance of 4,000,000 units (“Units“) of the Company to raise $200,000 at a price of $0.05 per Unit by way of a non-brokered private placement (the “Offering“).

Each Unit consists of one common share of CryptoStar (a “Common Share“) and one common share purchase warrant of CryptoStar (a “Warrant“). Each Warrant entitles the holder to acquire one Common Share at a price of CAD $0.075 per Common Share for a period of 18 months from the date of issue.

The Offering is subject to TSX Venture Exchange approval. The securities issued in connection with the Offering are subject to a four-month hold period, in accordance with applicable securities laws.

CryptoStar intends to use the net proceeds from the Offering for business operations and expansion of its business, and for general working capital purposes.

About CryptoStar Corp.:

CryptoStar has cryptocurrency mining operations with data centres located in the U.S.A. and Canada. CryptoStar is currently dedicated to becoming one of the lowest cost cryptocurrency producers in North America and a major supplier of GPU and ASIC miners and mining hardware & hosting packages worldwide.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, “expects”, “is expected”, “anticipates”, “intends”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may” or “will” be taken, occur or be achieved. Forward-looking statements include those relating to the use of net proceeds from the Offering. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward looking statements. Except as required by law, CryptoStar undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE CryptoStar Corp.

January 5, 2021 8:19 am

Asetek – Update to Full Year 2020 Guidance

PR Newswire

OSLO, Norway, Jan. 5, 2021 /PRNewswire/ — Asetek today updated its full-year 2020 revenue and pre-tax profit expectations due to continued strong demand in the fourth quarter.

Asetek expects to report an increase in Group revenue of 33-35% for 2020 compared with 2019. Gross margin is expected to increase from 2019, and the Company expects an income before tax of about $10-11 million.

The previous revenue and pre-tax profit expectations, announced on October 19, were for revenue growth of 25-30% in 2020 compared with 2019 and an expected income before tax of about $9-10 million.

The Company will release its fourth quarter and annual report for 2020 on February 24, 2021.

About Asetek

Asetek, the creator of the all-in-one liquid cooler, is the global leader for liquid cooling solutions for high performance gaming and enthusiast PCs, and environmentally aware data centers. Founded in 2000, Asetek is headquartered in Denmark and has operations in China, Taiwan and the United States. Asetek is listed on the Oslo Stock Exchange (ASETEK.OL).

For further information, please contact:

CEO and Founder André S. Eriksen
+45 2125 7076, email: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/asetek/r/asetek—update-to-full-year-2020-guidance,c3264377

The following files are available for download:

https://mb.cision.com/Main/6758/3264377/1356338.pdf

Release

View original content:http://www.prnewswire.com/news-releases/asetek–update-to-full-year-2020-guidance-301201047.html

SOURCE Asetek

January 5, 2021 8:18 am

NETSTREIT Corp. Provides Update on Fourth Quarter and Full Year 2020 Business Activities

NETSTREIT Corp. Provides Update on Fourth Quarter and Full Year 2020 Business Activities

– Introduces External Growth Target For 2021 –

DALLAS–(BUSINESS WIRE)–
NETSTREIT Corp. (NYSE: NTST) (the “Company”), a nationwide owner of high-quality, single-tenant net lease properties, today provided an update on the Company’s fourth quarter and full year 2020 business activities.

Fourth Quarter and Full Year 2020 Business Update

Operating Activity:

Collected 100.0% of rent payments for the months of October, November and December 2020
Maintained portfolio occupancy of 100.0% as of December 31, 2020

Portfolio Construction:

Fourth Quarter 2020 Portfolio Activity:

For the fourth quarter, the Company completed $81 million of acquisitions at an initial cash capitalization rate of 6.8%. Acquisitions completed during the quarter had a weighted-average remaining lease term of 8.8 years, with 68.7% of the properties occupied by investment grade rated tenants and 11.9% occupied by tenants with investment grade profiles (unrated tenants with more than $1.0 billion in annual sales and a debt to adjusted EBITDA ratio of less than 2.0x)
For the fourth quarter, the Company completed 12 dispositions for a total aggregate contractual sales price of $37 million, which equates to a 6.6% cash capitalization rate on occupied properties

Full Year 2020 Portfolio Activity:

For the full year 2020, the Company completed $409 million of acquisitions, of which 71.9% were occupied by investment grade rated tenants and 12.0% were occupied by tenants with investment grade profiles
For the full year 2020, the Company completed $50 million of dispositions

Year End Portfolio Position:

As of December 31, 2020, the NETSTREIT portfolio was comprised of 203 properties, contributing $41.8 million of annualized base rent¹, with a weighted-average remaining lease term of 10.5 years, of which 70.0% were occupied by investment grade rated tenants and 7.4% were occupied by tenants with investment grade profiles
As a result of NETSTREIT’s investment and asset management activities, the Company’s tenant diversification and tenant risk profile was enhanced throughout 2020. The Company’s ABR exposure to its largest tenant (7-Eleven, Baa1/AA- rated) was 8.9% as of December 31, 2020, as compared to 11.8% for its largest tenant (CVS Health, Baa2/BBB rated) as of December 31, 2019.
The Company’s exposure to the casual dining sector was reduced from 4.5% to 2.2% over the same time period
The Company continues to have no exposure to any theater, health club or early childhood education tenants.

Balance Sheet:

Ended the year with no outstanding balance on the Company’s revolving line of credit and a cash balance, including funds in 1031 exchange accounts, of $93 million
Completed a LIBOR swap to hedge floating rate exposure on the entire balance of the Company’s $175 million outstanding term loan through its December 2024 maturity

“After a landmark year in which we completed our 144A private offering, created a public company platform, and closed our initial public offering, we are very pleased with all we have accomplished at NETSTREIT in 2020. Our portfolio operations, including collections, remain extremely strong and reflect the portfolio quality and defensive asset characteristics that are at the core of our strategy. Further, our performance in 2020 on both acquisitions and dispositions provides us with a significantly larger, more resilient and diversified asset base to support outsized growth as we begin 2021,” said Mark Manheimer, Chief Executive Officer of NETSTREIT. “We are very proud of our entire team and could not have achieved our success in 2020 without their hard work. We believe we enter the new year very well positioned to further build on our accomplishments.”

2021 Outlook

The Company is introducing the following external growth targets for full year 2021:

The Company expects net acquisition activity, inclusive of dispositions, to total $320 million
The Company expects to continue to review its portfolio and complete opportunistic dispositions to further improve portfolio diversification and mitigate risk

About NETSTREIT

NETSTREIT is a Real Estate Investment Trust (REIT) based in Dallas, Texas that specializes in acquiring single-tenant net lease retail properties nationwide. The growing portfolio consists of high-quality properties leased to e-commerce resistant tenants with healthy balance sheets. Led by a management team of seasoned commercial real estate executives, NETSTREIT aims to create the highest quality net lease retail portfolio in the country with the goal of generating consistent cash flows and dividends for its investors.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements concerning our business and growth strategies, investment, financing and leasing activities and trends in our business, including trends in the market for single-tenant, retail commercial real estate. Words such as “expects,” “anticipates,” “intends,” “plans,” “likely,” “will,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore such statements included in this press release may not prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that the results or conditions described in such statements or our objectives and plans will be achieved. For a further discussion of these and other factors that could impact future results, performance or transactions, see the information under the heading “Risk Factors” in our prospectus dated August 13, 2020, relating to our initial public offering, filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2020 and other reports filed with the SEC from time to time. Forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this press release. New risks and uncertainties may arise over time and it is not possible for us to predict those events or how they may affect us. Many of the risks identified herein and in our periodic reports have been and will continue to be heightened as a result of the ongoing and numerous adverse effects arising from the novel coronavirus (COVID-19). We expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein, to reflect any change in our expectations with regard thereto, or any other change in events, conditions or circumstances on which any such statement is based, except to the extent otherwise required by law.

__________________________________________

¹ Annualized base rent, or ABR, is calculated by multiplying (i) cash rental payments (a) for the month following the period shown plus (b) for properties under development, the first full month’s permanent cash rent contractually due after the development period by (ii) 12.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005546/en/

Investor Relations

[email protected]

972-597-4825

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Residential Building & Real Estate Construction & Property REIT

MEDIA:

January 5, 2021 8:18 am

VEREIT® Announces December Rent Collection of 97%, Tenant Credit and Transaction Activity Updates

Expects to Exceed the High End of Property Acquisition Pipeline Range of $300 Million

PR Newswire

PHOENIX, Jan. 5, 2021 /PRNewswire/ — VEREIT, Inc. (NYSE: VER) (“VEREIT” or the “Company”), a full-service real estate operating company which owns and manages one of the largest portfolios of single-tenant commercial properties in the U.S., announced its December rent collection, tenant credit and transaction activity updates.

Rent Collection and Tenant Credit Update as of December 31, 2020

VEREIT had received rent of approximately 97% for December, which includes approximately 2% to be paid in arrears by a Government agency tenant and is in line with October and November rent collection.
Tenants representing more than 10% of VEREIT’s annualized rental income received credit-positive news during the year including:

Red Lobster was purchased by Thai Union Group PCL, a publicly listed company, an investor group led by international restaurant executives, and Red Lobster Management.
Top Golf Entertainment Group entered into a merger agreement with Callaway, a publicly listed company, which is expected to close in early 2021.
Albertsons and Academy Sports completed their initial public offerings and are now publicly listed companies
GPM Investments, LLC’s (“GPM”) parent company, Arko Holdings, completed its business combination and is now a publicly listed company called ARKO Corp. GPM is a growing leader in the U.S. convenience store industry with multiple brands acquired.
Tractor Supply received public issuer ratings of BBB from S&P Global Ratings and Baa1 from Moody’s Investors Service. Inclusive of these new ratings, VEREIT’s investment grade tenancy increased from 37.7% to 39.2% and from 46.4% to 49.7% within retail.

Transaction Activity Update as of December 31, 2020

Invested approximately $1.0 billion of capital during 2020, including $280 million acquired for the institutional partnerships and $400 million allocated to the redemption of 6.7% preferred stock, of which $100 million will be redeemed on January 15, 2021.

Expected to exceed the high end of Q4 2020 to Q1 2021 property acquisition pipeline of $150 million to $300 million with approximately $180 million completed in Q4 2020 at a cap rate of approximately 7%.

As part of the Company’s planned disposition program to reduce office from the current 17% of annualized rental income to below 15%, VEREIT sold approximately $53 million during the fourth quarter and has an additional $100 million under contract with the total approximate cap rate averaging 6%. Once completed, this will bring total office dispositions since the beginning of 2020 to approximately $430 million.

About VEREIT

VEREIT is a full-service real estate operating company which owns and manages one of the largest portfolios of single-tenant commercial properties in the U.S. VEREIT has total real estate investments of $14.6 billion including approximately 3,800 properties and 88.9 million square feet. VEREIT’s business model provides equity capital to creditworthy corporations in return for long-term leases on their properties. VEREIT is a publicly traded Maryland corporation listed on the New York Stock Exchange. VEREIT uses, and intends to continue to use, its Investor Relations website, which can be found at www.VEREIT.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Additional information about VEREIT can be found through social media platforms such as Twitter and LinkedIn.

About the Data

Rent collection percentages disclosed are based on contractual rent and recoveries paid by tenants to cover estimated tax, insurance and common area maintenance expenses, including the Company’s pro rata share of such amounts related to properties owned by unconsolidated joint ventures. Percentages are calculated using a denominator that reflects pre-COVID-19 rents that has not been adjusted for any rent relief granted. Amounts exclude any tenants in bankruptcy prior to the pandemic.

Forward-Looking Statements

Information set forth in this press release contains forward-looking statements which reflect VEREIT’s expectations and projections regarding future results, events and plans, including but not limited to statements regarding its acquisition pipeline, expected dispositions (including the reduction of its office portfolio), and the future redemption of preferred stock. Generally, the words “anticipates,” “assumes,” “believes,” “continues,” “could,” “estimates,” “expects,” “goals,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “targets,” “will,” variations of such words and similar expressions identify forward-looking statements. These forward-looking statements are based on information currently available and involve a number of known and unknown assumptions and risks, uncertainties and other factors, which are difficult to predict and beyond VEREIT’s control, that could cause actual events and plans or could cause VEREIT’s business, financial condition, liquidity and results of operations to differ materially from those expressed or implied in the forward-looking statements. Further, information regarding historical rent collections should not serve as an indication of future rent collections. These factors include the risks and uncertainties detailed from time to time in VEREIT’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available at the SEC’s website at www.sec.gov. VEREIT disclaims any obligation to publicly update or revise any forward-looking statements contained in this press release whether as a result of changes in underlying assumptions or factors, new information, future events or otherwise, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/vereit-announces-december-rent-collection-of-97-tenant-credit-and-transaction-activity-updates-301200857.html

SOURCE VEREIT, Inc.

January 5, 2021 8:18 am

Genpact Acquires Industry-Leading Data Engineering and Analytics Firm Enquero to Drive the Next Generation of Enterprise Digital Transformation

Acquisition will accelerate Genpact’s ability to leverage data and cloud technologies to drive digital transformation services through advanced analytics

PR Newswire

NEW YORK, Jan. 5, 2021 /PRNewswire/ — Genpact (NYSE: G), a global professional services firm focused on delivering digital transformation, today announced that it has acquired Enquero, a firm that offers data engineering and data-led digital transformation services.

“Today’s announcement increases the scale and depth of our data and analytics teams and further enhances our capabilities to accelerate the digital transformation journeys of our clients,” said ‘Tiger’ Tyagarajan,chief executive officer of Genpact. “I am excited that Arvinder Pal Singh and the very talented Enquero team are joining Genpact at a time when we are seeing strong demand from our clients for exactly these types of solutions to help them navigate and win in challenging markets.”

This acquisition comes as businesses are contending with an ever-increasing volume and complexity of data – external and internal, structured and unstructured. In an environment where organizations across industries and geographies are experiencing unprecedented volatility — from supply and demand challenges, to seismic shifts in customer expectations and business models – the smart use of data at the core of an organization will be critical to business growth.

With notable strengths in industries such as high tech and consumer goods, Enquero extends Genpact’s strong foundation of existing capabilities in delivering end-to-end transformation to enterprise clients. These capabilities make the acquisition of Enquero especially timely as many businesses are looking to harness data, cloud technologies, and analytics to drive growth and be more resilient, agile, and connected.

“Enquero enables our clients’ strategies to succeed through orchestrating data, process, and technology in a connected digital ecosystem. We started Enquero in 2014 in Silicon Valley to help organizations better leverage data and cloud technologies,” said Enquero Chief Executive Officer Arvinder Pal Singh. “Joining Genpact is the logical next step for us. Genpact’s domain, process and technology leadership, global footprint, scale, and extensive client base will help both Genpact and Enquero, as a combined force, scale our solutions to transform even more organizations.”

Singh will continue to lead the business, which will be rebranded Enquero, a Genpact company, and all Enquero employees will join Genpact.

Terms of the transaction were not disclosed. True Blue Partners was the exclusive financial advisor to Enquero on this transaction.

For more information, please visit www.genpact.com and www.enquero.com.

About Enquero
Founded in April 2014 and headquartered in Milpitas, California, Enquero is a global technology solutions company that builds platforms around data, design, and digital experiences. It offers digital engineering, data engineering and analytics, consulting and architecture, and enterprise apps solutions to enterprise clients around the world.

About Genpact
Genpact (NYSE: G) is a global professional services firm that makes business transformation real. We drive digital-led innovation and digitally-enabled intelligent operations for our clients, guided by our experience running thousands of processes primarily for Global Fortune 500 companies. We think with design, dream in digital, and solve problems with data and analytics. Combining our expertise in end-to-end operations and our AI-based platform, Genpact Cora, we focus on the details – all 90,000+ of us. From New York to New Delhi and more than 30 countries in between, we connect every dot, reimagine every process, and reinvent companies’ ways of working. We know that reimagining each step from start to finish creates better business outcomes. Whatever it is, we’ll be there with you – accelerating digital transformation to create bold, lasting results – because transformation happens here. Get to know us at Genpact.com and on LinkedIn, Twitter, YouTube, and Facebook.

Safe Harbor
This press release contains certain statements concerning Genpact’s future expectations, plans and prospects that constitute forward-looking statements, as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking terms such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “may,” “shall,” “will,” “would” and variations of such words and similar expressions, or the negative of such words or similar expressions. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those in such forward-looking statements. These risks, uncertainties and other factors include but are not limited to the accuracy of our assumptions about trends in our market, our ability to successfully consummate or integrate strategic acquisitions, our ability to achieve expected benefits from strategic acquisitions, our ability to manage growth, our ability to implement and derive revenues from new service offerings, as well as other risks detailed in our reports filed with the U.S. Securities and Exchange Commission, including Genpact’s Annual Report on Form 10-K. These filings are available at www.sec.gov. Genpact may from time to time make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. Although Genpact believes that these forward-looking statements are based on reasonable assumptions, you are cautioned not to put undue reliance on these forward-looking statements, which reflect management’s current analysis of future events and should not be relied upon as representing management’s expectations or beliefs as of any date subsequent to the time they are made. Genpact undertakes no obligation to update any forward-looking statements that may be made from time to time by or on behalf of Genpact.

MEDIA CONTACTS:

Michael Schneider

Genpact Global Communications

+1 217-260-5041

[email protected]

Siya Belliappa

Genpact Media Relations – India

+91 9823133365

[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/genpact-acquires-industry-leading-data-engineering-and-analytics-firm-enquero-to-drive-the-next-generation-of-enterprise-digital-transformation-301200822.html

SOURCE Genpact

January 5, 2021 8:18 am

Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada

Agreement incorporates TYMLOS^® and abaloparatide-TD
Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties
Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S. and Japan; a key focus area for the company for 2021

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc (“Endo”) (NASDAQ: ENDP), to register, commercialize, and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc. (“Paladin”), an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the terms of the agreements, Paladin will pay Radius upfront and milestone payments up to approximately $8.0 million and tiered royalties up to the mid-twenties on net sales in Canada.

In accordance with the terms of the agreements, Paladin will license Radius’ abaloparatide subcutaneous injection, TYMLOS^®, and abaloparatide novel transdermal device (“abaloparatide-TD”) for the Canadian market. Paladin will be responsible for the registration distribution, sales, marketing, medical affairs, pricing and reimbursement activities in connection with abaloparatide. Radius will be responsible for supplying the drug to Paladin.

“Reaching an agreement with Paladin in Canada demonstrates both the interest in and opportunity to expand the global footprint of abaloparatide in select ex-U.S. markets. This is one of several key priorities for us and our goal is to make additional progress throughout 2021,” said Cole Ikkala, Head of Business Development at Radius.

Paladin is targeting to file a New Drug Submission (NDS) to Health Canada for TYMLOS® by the first quarter of 2022. The Company will provide additional business updates as and when appropriate.

About TYMLOS
^®
(abaloparatide) Injection

TYMLOS^® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF OSTEOSARCOMA

Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats. The effect was observed at systemic exposures to abaloparatide ranging from 4 to 28 times the exposure in humans receiving the 80-mcg dose. It is unknown if TYMLOS will cause osteosarcoma in humans.
The use of TYMLOS is not recommended in patients at increased risk of osteosarcoma including those with Paget’s disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton.
Cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.

Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.

Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.

Hypercalciuria and Urolithiasis: TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

Adverse Reactions: The most common adverse reactions (incidence ≥2%) are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.

INDICATIONS AND USAGE

TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.

Limitations of Use

Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.

For the TYMLOS prescribing information, including Boxed Warning, please visit www.tymlospi.com.

About Abaloparatide-TD and wearABLe Phase 3 Study

Abaloparatide-TD was developed in a collaboration between Radius and Kindeva Drug Delivery (“Kindeva”) (formerly 3M Drug Delivery Systems) with the application of Kindeva’s innovative microstructured transdermal patch technology. The Phase 3 wearABLe abaloparatide-TD study is the first pivotal study to evaluate treatment using a novel non-injectable delivery of an anabolic therapy. The wearABLe Phase 3 study is a pivotal, randomized, open label, active-controlled, bone mineral density (“BMD”) non-inferiority bridging study that will evaluate the efficacy and safety of abaloparatide-TD versus TYMLOS^® (abaloparatide) injection in approximately 500 patients with postmenopausal osteoporosis at high risk for fracture. The primary endpoint of the study is the percentage change in lumbar spine BMD at 12 months.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. For more information, please visit www.radiuspharm.com.

About Endo and Paladin Labs Inc.

Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing and sales organization that has helped it evolve into one of Canada’s leading specialty pharmaceutical companies. Paladin is an operating company of Endo International plc. For more information visit: www.endo.com or www.paladin-labs.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing of Paladin’s NDS and approval. These forward-looking statements are based on management’s current expectations. These statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the results of regulatory submissions and oversight; success of our commercial operations; success of our clinical trials and preclinical studies; risks related to manufacturing, supply and distribution; success of any collaboration, partnership, license or similar agreements; achievement of milestones; receipt of royalties or other future contingent payments; ability to implement pricing increases. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ending December 31, 2019 and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact:

Peter Schwartzman
Email: [email protected]
Phone: 617-583-2017

January 5, 2021 8:13 am

Radix IoT, REIG Launch REvolution IoT™ Turn-Key IoT Monitoring Portal for Mid-Scale Utility Solar Installations

REvolution IoT Software Platform is Part of REnergyWare™ DAS/SCADA Monitoring, Management Software, RESource™ Digital Operations and Maintenance Services for Asset Management, Production Insights, Reporting, and Alerting

DALLAS, Jan. 05, 2021 (GLOBE NEWSWIRE) — Radix IoT–offering limitless monitoring and management rooted in intelligence–and Renewable Energy Integration Group (REIG)– design, engineering, and DAS/SCADA hardware providers for utility scale solar developers–have joined forces in launching REvolution IoT™. As a tailored version of Radix IoT’s Mango platform, included in REnergyWare, REIG’s new division providing packaged hardware assemblies, DAS/SCADA monitoring and control, REvolution IoT software platform and RESource™ digital Operations and Maintenance (O&M) services will reduce operational costs, maximize return on investment, and improve efficiencies for mid-to-large-scale solar PV industry customers.

“In partnership with Radix IoT, our REnergyWare division will provide monitoring and management software and digital O&M services to 1MW to 20+MW mid-scale utility solar PV installations,” said Keith Davis, President and CEO, REIG. “Adding the REvolution IoT software monitoring platform and services to our legacy offerings, we are well positioned to be at the forefront of national, and in the future, global, IoT solutions providers to solar PV markets.”

Since 2008, U.S. installations have grown 35-fold to over 2,500 utility-scale solar photovoltaic (PV) electricity generating facilities nationwide, with an estimated 62.5 gigawatts (GW) today–enough capacity to power 12 million average American homes. As solar plants expand in size and complexity, REnergyWare’s turn-key monitoring portal for utility scale solar installations will combine the Radix IoT platform and software development expertise with REIG’s PV industry hardware expertise. REnergyWare meets the PV industry’s critical need for a comprehensive software platform for asset management, production insights, customized reporting, and alerting, coupled with a digital operations and maintenance service.

“With REvolution IoT, REIG customers will now reap the benefits from real-time and historical analytics provided by the Radix IoT Platform, allowing unparalleled monitoring and management of solar installations on scale,” said Joel Haggar, Chief Strategy Officer, Radix IoT. “With REIG’s expertise and reputation in the solar industry and customer reach, the partnership enables up to the minute management of installations to ensure uptime and allow for continuous operational criteria to be met on scale.”

RESource Digital O&M will provide the remote monitoring and management of the solar assets and networked systems from REIG’s Charlotte, NC operations center. In the event of problems or alarms, REvolution IoT will allow REnergyWare engineers to remotely diagnose and troubleshoot the problem before dispatching field technicians to the site. With IoT technologies now becoming commonplace to control operational expense and service costs remotely in many industries, the partnership between Radix IoT and REIG exemplifies the combined power of a recognized and trusted IoT Platform from Radix IoT (commonly used in power distribution, telecommunications, and smart building infrastructure), and that of REIG, a leader in utility scale solar PV.

“After months of software evaluations, REIG selected to partner with Radix IoT to develop REvolution IoT™– a tailored version of Radix IoT’s Mango platform– to deliver critical dashboards and reports to our existing client base, while tapping the growing small to medium solar PV market nationwide,” states Rene Robaina, COO, REIG.

For more information visit Radix IoT www.radixiot.com or contact [email protected].  
 
Radix IoT Resources 
Radix IoT Products
Radix IoT Markets
Radix IoT Case Studies

About Renewable Energy Integration Group, LLC

Based in Charlotte, NC, Renewable Energy Integration Group (“REIG”), in operation since 2016, provides UL listed DAS/SCADA hardware assemblies, system design, installation, commissioning, and service to the large and utility scale solar PV industry. For more information visit https://reig-us.com/

About REnergyWare™

REnergyWare™ is a formal division of REIG, which in addition to selling the REIG packaged hardware assemblies, will also provide the DAS/SCADA monitoring and control REvolution IoT™ software platform, and the RESource™, digital O&M services to the mid- to large- scale solar PV industry, reducing operational costs and improving efficiencies for its customers. For more information visit www.REnergyWare.com

About Radix IoT 
Radix IoT offers a flexible and unified IoT platform to unite and harness data from existing subsystems into a managed dashboard allowing remote monitoring, process management, and data aggregation intelligence to maximize uptime operations and minimize operating expenses. From one location to multiple, the Radix IoT portfolio of products solves the inherent complexity of managing geographically distributed facilities across various markets, including edge data centers, utilities, carrier edge/telecom infrastructure, industrial, and property management. Radix IoT is a wholly owned subsidiary of Compass Datacenters. It is headquartered in Dallas, TX, with offices in Mountain View (CA) and Chicago (IL). For more information, visit www.radixiot.com and Follow on Twitter, Facebook and LinkedIn.

Media Contact: 
Jackie Abramian  
Global Cadence (for Radix IoT)  
[email protected]   
617-584-2580  

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e40ed3f0-d8f2-4439-977c-00d4b3084b4b

January 5, 2021 8:13 am

Radix IoT, REIG Launch REvolution IoT™ Turn-Key IoT Monitoring Portal for Mid-Scale Utility Solar Installations

REvolution IoT Software Platform is Part of REnergyWare™ DAS/SCADA Monitoring, Management Software, RESource™ Digital Operations and Maintenance Services for Asset Management, Production Insights, Reporting, and Alerting

For more information visit Radix IoT www.radixiot.com or contact [email protected].  
 
Radix IoT Resources 
Radix IoT Products
Radix IoT Markets
Radix IoT Case Studies

Media Contact: 
Jackie Abramian  
Global Cadence (for Radix IoT)  
[email protected]   
617-584-2580  

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e40ed3f0-d8f2-4439-977c-00d4b3084b4b

January 5, 2021 8:10 am

Asetek A/S Announces Transactions Carried Out Under the Current Share Buyback Programme in Accordance With the “Safe Harbour Method”

PR Newswire

OSLO, Norway, Jan. 5, 2021 /PRNewswire/ — On October 23, 2020, Asetek A/S launched a share buyback programme, as described in company announcement of October 23, 2020. According to the programme, Asetek A/S will in the period until March 5, 2021 buy back own shares up to a maximum value of USD 4 million and with a maximum of 381,000 shares. The share buyback programme will be implemented in accordance with Regulation (EU) no. 596/2014 of 16th April 2014 of the European Parliament and Council and ommission Delegated Regulation (EU) no. 2016/1052, also referred to as the Safe Harbour rules.


Trading day		Number of shares bought back	Average purchase price (NOK)	Amount (USD)
Total, latest announcement		173,909	89.1383	1,719,357.92
45:	28 December 2020	5,000	99.4901	57,604.77
46:	29 December 2020	4,000	103.4236	48,071.29
47:	30 December 2020	4,000	104.4508	48,757.63
Total accumulated over week 53/2020		13,000	102.2268	154,433.69
Total accumulated during the share buy-back programme		186,909	90.0486	1,873,791.61

With the transactions stated above, the Company owns a total of 1,021,156 shares as treasury shares, corresponding to 3.86% of the share capital. See the enclosure for information about the individual transactions made under the share buyback programme.

About Asetek

Asetek is the global leader in liquid cooling solutions for gaming and enthusiast PCs, data centers and servers. Founded in 2000, Asetek is headquartered in Denmark and has operations in California, Texas, China and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASTK.OL).

www.asetek.com

For further information, please contact:

Peter Dam Madsen, Chief Financial Officer
Mobile: +45 2080 7200, e-mail: [email protected]
Asetek A/S
Assensvej 2
DK-9220 Aalborg East
Denmark

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/asetek/r/asetek-a-s-announces-transactions-carried-out-under-the-current-share-buyback-programme-in-accordanc,c3264366

The following files are available for download:

https://mb.cision.com/Main/6758/3264366/1356332.pdf	Release
https://mb.cision.com/Public/6758/3264366/bed8088f50074e2e.pdf	Week 53

View original content:http://www.prnewswire.com/news-releases/asetek-as-announces-transactions-carried-out-under-the-current-share-buyback-programme-in-accordance-with-the-safe-harbour-method-301201038.html

SOURCE Asetek